Drug Trial Radar · NCT05076682
Reverse Triple Negative Immune Resistant Breast Cancer
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Jun 30, 2022
Primary completion
Dec 31, 2026
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 13, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase II, open-label, nine-arm parallel study evaluating the efficacy and safety of combined treatment (sodium cromoglicate, choline, efavirenz, SHR 1811, SHR 2102, mecapegfilgrastim, theophylline, mifepristone) with immune checkpoint inhibitor or immune checkpoint inhibitor rechallenge(AK131) in mTNBC (triple negative breast cancer) patients who progressed during previous immune checkpoint inhibitors.
Conditions
- Triple-negative Breast Cancer
Interventions
CholineDrug
Choline 300mg tid or 500mg bid, p.o
anti-PD-1 antibody and chemotherapyDrug
PD-1 antibody SHR1210 200mg q2w chemotherapy (whether and which should be given depends on the treatment regimen before enrollment)
Sodium CromoglicateDrug
Sodium Cromoglicate will be administered intranasally (nasal spray) (5 spray each nostril 4 times a day, 1 mg/spray)
EfavirenzDrug
Efavirenz 600mg qd, p.o
SHR-A1811Drug
4.8mg/kg q3w
SHR-A2102Drug
6mg/kg q3w
SHR-1316Drug
1200mg q3w
MecapegfilgrastimDrug
Mecapegfilgrastim, 6mg, d3, q3w, s.c.
AK131Drug
AK131, 40mg/kg i.v., q2w
TheophyllineDrug
Theophylline, 100mg bid, p.o.
MifepristoneDrug
Mifepristone, 200mg, qd, d1-3, qw, p.o.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR)Time frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months
- Immune changes in peripheral bloodTime frame: Baseline until disease progression or loss of clinical benefit, assessed up to 6 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.